The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought
Abstract
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic (semaglutide; Novo Nordisk), Wegovy (semaglutide; Novo Nordisk) and Mounjaro (tirzepatide; Eli Lilly) have been propelled to the forefront of both medical innovation and public discussion. The surging demand for GLP-1s, fuelled in part by social media amplification and celebrity endorsement, has collided with constrained […]
Fields of Study & Subjects
Eating Disorders and Behaviors
Pharmacology and Obesity Treatment
Diabetes Treatment and Management
Publication details
- Journal / source
- Pharmaceutical journal/The pharmaceutical journal
- Publication date
- 1 January 2026
- Language
- EN